Catalyst Wire Dossier Catalyst Wire Dossier

PRN473

SAR444727 · Principia Biopharma, a Sanofi Company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PRN473, covering 2024-03-01 to 2024-03-01. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis [Phase 2]

See pricing